CMC Biopharmaceuticals gains new investment  

The Copenhagen based biotech contract manufacturing company has received a DKK 106 mn investment

CMC Biopharmaceuticals, a Copenhagen based biotech contract manufacturing company, has received a DKK 106 mn (USD 19 mn) investment. The cash will be used to cover a deficit from 2004 as well as preparing CMC for new growth opportunities. Investors comprise the French venture company Innoven Partenaires and the Danish investment company Catpen. Both are new investors in CMC and in the Danish biotech sector.


Jesper Zeuthen, director of biotech funds at BankInvest, a major shareholder of CMC, says the new investment means the company will not need more money: "The order books for 2005 are close to being full, generated revenues are passing DKK 100 mn (USD 18 mn) and CMC has reached a size where it is self-financing." The news is reported by daily financial newspaper Børsen.


Copenhagen-based CMC's facilities comprise a new factory for manufacturing and control of active pharmaceutical ingredients used in drugs in clinical trial phases I, II and III. CMC also operates a laboratory in Science Park Symbion, Copenhagen and has sales offices in UK and the US. The biotech company has a workforce of approx. 100 people.


Link > CMC Biopharmaceuticals 

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×